Free Trial

Corbus Pharmaceuticals (CRBP) News Today

Corbus Pharmaceuticals logo
$5.52 -0.27 (-4.66%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$5.60 +0.08 (+1.36%)
As of 03/28/2025 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Consensus Rating of "Buy" by Brokerages
Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have been given a consensus rating of "Buy" by the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy recommendation and one has issued a str
Corbus announces first patient dosed in Phase 1 CRB-913 study
Corbus Pharmaceuticals Holdings, Inc. stock logo
B. Riley Lifts Earnings Estimates for Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at B. Riley raised their FY2025 earnings estimates for shares of Corbus Pharmaceuticals in a research report issued to clients and investors on Thursday, March 13th. B. Riley analyst K. Patel now anticipates
Corbus Pharmaceuticals Holdings, Inc. stock logo
HC Wainwright Issues Positive Estimate for CRBP Earnings
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now forecasts that the
Corbus Pharmaceuticals Holdings, Inc. stock logo
What is B. Riley's Forecast for CRBP Q1 Earnings?
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Analysts at B. Riley issued their Q1 2025 EPS estimates for Corbus Pharmaceuticals in a research report issued to clients and investors on Thursday, March 13th. B. Riley analyst K. Patel anticipates that the biopharmaceutical com
Corbus Pharmaceuticals Holdings, Inc. stock logo
What is Lifesci Capital's Estimate for CRBP Q1 Earnings?
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Stock analysts at Lifesci Capital boosted their Q1 2025 EPS estimates for Corbus Pharmaceuticals in a research report issued on Tuesday, March 11th. Lifesci Capital analyst M. Belghiti now forecasts that the biopharmaceutical com
Corbus Pharmaceuticals Holdings, Inc. stock logo
Wedbush Reaffirms Outperform Rating for Corbus Pharmaceuticals (NASDAQ:CRBP)
Wedbush reissued an "outperform" rating and issued a $51.00 price target on shares of Corbus Pharmaceuticals in a research note on Wednesday.
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals (NASDAQ:CRBP) Receives "Buy" Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and issued a $50.00 price target (down previously from $75.00) on shares of Corbus Pharmaceuticals in a report on Wednesday.
Corbus Pharmaceuticals (CRBP) Gets a Buy from RBC Capital
Corbus Pharmaceuticals Holdings, Inc. stock logo
Jefferies Financial Group Lowers Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $53.00
Jefferies Financial Group dropped their target price on shares of Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating on the stock in a research report on Tuesday.
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals (NASDAQ:CRBP) Posts Quarterly Earnings Results, Beats Expectations By $0.24 EPS
Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping analysts' consensus estimates of ($1.02) by $0.24.
Corbus Pharmaceuticals (CRBP) Gets a Buy from William Blair
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded to Sell at StockNews.com
StockNews.com upgraded shares of Corbus Pharmaceuticals to a "sell" rating in a research report on Thursday.
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Buy" by Analysts
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has received an average recommendation of "Buy" from the ten brokerages that are covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation and one has given a strong bu
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday
Corbus Pharmaceuticals (NASDAQ:CRBP) will be releasing earnings before the market opens on Tuesday, March 11, Financial Modeling Prep reports.
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals (NASDAQ:CRBP) Earns Outperform Rating from Analysts at William Blair
William Blair began coverage on shares of Corbus Pharmaceuticals in a research note on Friday. They set an "outperform" rating for the company.
Corbus Pharmaceuticals initiated with an Outperform at William Blair
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals (NASDAQ:CRBP) Given Buy Rating at HC Wainwright
HC Wainwright restated a "buy" rating and set a $75.00 price target on shares of Corbus Pharmaceuticals in a report on Tuesday.
Corbus Pharmaceuticals announces data from its US, UK study of CRB-701
RBC Capital Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals Holdings, Inc. stock logo
Equities Analysts Set Expectations for CRBP FY2029 Earnings
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a research report issued to clients and investors on Monday, February 10th. HC Wainwright analyst A.
Corbus Pharmaceuticals announces clinical data for CRB-701
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals' (CRBP) "Buy" Rating Reaffirmed at HC Wainwright
HC Wainwright restated a "buy" rating and issued a $75.00 target price (down previously from $80.00) on shares of Corbus Pharmaceuticals in a research note on Monday.
Corbus Pharmaceuticals (CRBP) Receives a Buy from H.C. Wainwright
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of "Buy" by Analysts
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has been given an average rating of "Buy" by the nine ratings firms that are covering the company, Marketbeat reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to
Piper Sandler Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Short Interest Down 9.1% in January
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) saw a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 2,410,000 shares, a decline of 9.1% from the December 31st total of 2,650,000 shares. Approximately 22.1% of the company's stock are sold short. Based on an average trading volume of 324,600 shares, the short-interest ratio is currently 7.4 days.
Corbus Pharmaceuticals Holdings, Inc. stock logo
Short Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Decreases By 9.1%
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 2,410,000 shares, a drop of 9.1% from the December 15th total of 2,650,000 shares. Currently, 22.1% of the company's stock are short sold. Based on an average daily volume of 324,600 shares, the days-to-cover ratio is presently 7.4 days.
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of "Buy" by Brokerages
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has earned a consensus recommendation of "Buy" from the nine brokerages that are currently covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating and one has given a strong bu
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Sees Significant Growth in Short Interest
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 2,650,000 shares, an increase of 5.6% from the November 30th total of 2,510,000 shares. Currently, 24.3% of the shares of the company are short sold. Based on an average daily trading volume, of 448,900 shares, the days-to-cover ratio is currently 5.9 days.
Remove Ads
Get Corbus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.

CRBP Media Mentions By Week

CRBP Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRBP
News Sentiment

0.64

0.81

Average
Medical
News Sentiment

CRBP News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRBP Articles
This Week

4

3

CRBP Articles
Average Week

Remove Ads
Get Corbus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CRBP) was last updated on 3/30/2025 by MarketBeat.com Staff
From Our Partners